Mandy Jackson

San Diego

Managing Editor, US Commercial News at Scrip

Managing Editor, US Commercial News at The Pink Sheet

I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.

Featured in: Favicon

informa.com (+4) Favicon

pharmamedtechbi.com Favicon

clinicalleader.com Favicon

citeline.com Favicon

xconomy.com Favicon

invivo.citeline.com

Articles

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

5 days ago | insights.citeline.com | Mandy Jackson

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN First-In-Class Drug Exceeds ExpectationsVera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria. Vera plans to develop atacicept in other indications, including kidney diseases beyond IgAN (Shutterstock)
Finance Watch: Public Company Fundraising Sank Across The Board In Q1

2 weeks ago | insights.citeline.com | Mandy Jackson

Finance Watch: Public Company Fundraising Sank Across The Board In Q1Private Firms Outperformed, With Mixed ResultsPublic Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.
Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

2 weeks ago | insights.citeline.com | Mandy Jackson

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m GoalDDF-2 Will Fund Up To 15 Start-UpsPrivate Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

2 weeks ago | insights.citeline.com | Mandy Jackson

Finance Watch: Prime, Kyverna, Allogene And More Announce Job CutsEnliven, Arcturus Discontinue Programs To Save CashRestructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.
First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

2 weeks ago | insights.citeline.com | Mandy Jackson

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid DrugsEarly Diagnosis Key To Treating Mild Cognitive ImpairmentThe US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses. Anti-amyloid drug prescribers can now diagnose Alzheimer's pathology with a blood test rather than a PET scan or CSF test (Shutterstock)
BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

3 weeks ago | insights.citeline.com | Mandy Jackson

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy BusinessFirst Deal Under Business Development PushBioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus. BioMarin is assessing several deals in addition to Inozyme (Shutterstock)
Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

3 weeks ago | insights.citeline.com | Mandy Jackson

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand ExpandsPrimary Care, Blood-Based Biomarkers Key To GrowthEisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25. Primary care physician outreach is the next frontier in Eisai's Leqembi launch (Shutterstock)
AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

3 weeks ago | insights.citeline.com | Mandy Jackson

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA TherapeuticsCollaboration Across CNS, Immunology, OncologyADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals. AbbVie and ADARx plan to combine their capabilities to develop siRNA medicines (Shutterstock)
Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

3 weeks ago | insights.citeline.com | Mandy Jackson

Finance Watch: Funding Alternatives Become The Norm In Tough Public MarketsVivo’s Public Fund Has $740m For Small To Mid-CapsPublic Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.
Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

3 weeks ago | insights.citeline.com | Mandy Jackson

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To EaseFurther Investment Depends On US Policy ShiftsRoche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma. Further Roche investments at Holly Springs, NC and elsewhere in the US may change based on future policy decisions (Shutterstock)